Merck MRK is going to face a major patent cliff, as its blockbuster PD-L1 therapy Keytruda is nearing loss of exclusivity ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

But nearly half of Merck's revenue is generated by a single product. That's oncology drug Keytruda, which has turned out to ...

Are things finally looking up for Merck (NYSE: MRK)? After being mostly southbound for the better part of the last two years, ...

Keytruda sales totaled $5,795 million in Q1 2023, up 17% year-on-year, thanks partly to an increase in its indications for use. At the same time, Robert Davis does not actively use the share buyback ...

Merck & Co. Inc. on Monday gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.’s top-selling products. The Food and Drug Administration on Monday ...

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., ...

Rahway: Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., ...

We issued an updated research report on Merck & Co., Inc.MRK on Oct 7. The leading pharmaceutical company has made significant progress with its pipeline and is working on bringing new products to ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced its intention to spin-off products from its Women’s Health, trusted Legacy ...

Company Announces Third-Quarter 2007 Earnings Per Share (EPS) of $0.75, Excluding Restructuring Charges; Third-Quarter Reported EPS of $0.70 Twelve Percent Revenue Growth Driven by Key Products ...